Name: Latest research reports of Indegene Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Indegene Ltd.
Rating: 3
Author: Motilal Oswal

Indegene Ltd.

NSE: INDGN | BSE: 544172 | ISIN: INE065X01017 | Industry: Healthcare Services
| Mid-range Performer

601.7500 29.85 (5.22%)

NSE Oct 26, 2026 15:31 PM

Near 52W High of ₹627.00

Volume: 528.3K

Indegene Ltd.

31 Jan 2026

601.75

5.22%

Acquisition drives growth with steady organic performance

Neutral: Indegene Ltd.

Motilal Oswal

Indegene’s 3QFY26 USD revenue rose 15.1% QoQ, aided by the BioPharm acquisition, while organic USD revenue growth stood at 4% QoQ (below our estimate).

Indegene has gained 22.15% in the last 3 Months